1.
First Quarter Fiscal 2013
Earnings Conference Call
March 6, 2013
www.nordion.com

2.
Caution on Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of applicable securities laws, including under
applicable Canadian securities laws and the “safe harbor” provisions of the United States Private Securities Litigation Reform Act
of 1995. These statements can be identified by expressions of belief, expectation or intention, as well as those statements that are
not historical fact. The words “may”, “will”, “could”, “should”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”
and similar words and expressions are also intended to identify forward-looking statements. Forward-looking statements are
necessarily based on estimates and assumptions made by us in light of our experience and our perception of historical trends,
current conditions and expected future developments, as well as other factors that we believe are appropriate in the
circumstances, but which are inherently subject to significant business, political, economic and competitive uncertainties and
contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-
looking statements. Accordingly, this presentation is subject to the disclaimer and qualified by the assumptions, qualifications and
risk factors referred to in our 2012 Annual Information Form (AIF).
We caution readers not to place undue reliance on the Company’s forward-looking statements, as a number of factors could
cause our actual results, performance or achievements to differ materially from any forward-looking statements. We do not
assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to
time by us or on our behalf, except as required by applicable law.
2

3.
Non GAAP Information
To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the
company uses non-GAAP financial measures such as adjusted net income and adjusted earnings per share. Non-GAAP financial
measures exclude certain items, such as restructuring charges and recovery, change in fair value of embedded derivatives, AECL
arbitration and legal fees, loss and gains on sales of investments, loss or gains on discontinued operations, and tax effects on
adjusted items. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future
results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide
investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented.
Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily
comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the
corresponding measures calculated in accordance with GAAP.
3

4.
First Quarter Fiscal 2013
Earnings Conference Call
Steve West
Chief Executive Officer
March 6, 2013 www.nordion.com

5.
Q1 2013 Results
Targeted Therapies Sterilization Technologies Medical Isotopes
Segmented Revenue Segmented Earnings*
(US$ millions) (US$ millions)
60 18
16
50
16.4 14
16.1
4.5
40 12
10 3.5
30
8
25.9 25.2
7.7
20 6
6.9
4
10
11.0 12.0 2 3.1
1.4
0 0
2012 2013 2012 2013
Q1 Q1
* Excludes corporate segmented loss 5

6.
Targeted Therapies: TheraSphere®
• $12.0 million in • Annual growth in the
revenue up 9% over mid-teen percent
2013 OUTLOOK
Q1 RESULTS
Q1/12 range
• Added 4 new sites in • Growth in the
the U.S. and 6 in second half of fiscal
EMEA 2013 will be stronger
• Launched new global than in the first half
TheraSphere® website of the year
• Initiated STOP-HCC
clinical trial sites in
Canada and Europe
STRATEGY
Build the Targeted Therapies
business.
6

7.
Specialty Isotopes: Sterilization Technologies
• $16.4 million revenue up • Maintain market-
2% compared to Q1/12 leading position and
2013 OUTLOOK
continue generating
Q1 RESULTS
• Cobalt revenue of $15.4
million decreased 2% high margins
over Q1/12 • Strengthen
• $1.1 million in relationships with
Sterilization – Other current customers and
revenue due to enter into new and
refurbishment work emerging markets
performed on existing • Selectively grow
production irradiators gamma sterilization
sales over the long-
term
STRATEGY
Maintain cash generation
and selectively invest in
growth. 7

8.
Specialty Isotopes: Medical Isotopes
• $25.2 million revenues, • Maintain medical
decreased 2.6% isotopes sales by
working closely with
2013 OUTLOOK
compared with Q1
Q1 RESULTS
fiscal 2012 existing customers to
bring additional value
• Reactor isotopes
revenue was $20.4 • Explore strategic
million, a decrease of opportunities for
$0.5 million or 3% over cyclotron based
Q1/12 medical isotopes
• Contract manufacturing • Assess opportunities
revenues were up 6% to obtain reliable and
over Q1/12 long-term supply of
medical isotopes
STRATEGY
Optimize the value of the business.
8

9.
First Quarter Fiscal 2013
Earnings Conference Call
Peter Dans
Chief Financial Officer
March 6, 2013 www.nordion.com

10.
Q1 2013 Financial Performance
Q1 Segmented Revenue
(US$ millions)
60
50
16.1 16.4
40
CONSOLIDATED RESULTS
30
25.9 25.2
20 • Q1 revenue of $53.7 million; up 1% over
10
11.0 12.0
Q1/12
0
2012 2013 • GAAP net loss of $0.3 million
Q1 Segmented Earnings* • Adjusted net income of $4.1 million down
(US$ millions)
20 from $7.1 million over Q1/12
15 • Non-GAAP EPS decreased to $0.07
4.5
compared with $0.11 non-GAAP EPS in
10 3.5
7.7
Q1/12
5 6.9
• Gross margin percentages were 52% in
3.1
0 1.4 Q1/13
2012 2013
Targeted Sterilization Medical
Therapies Technologies Isotopes
*EXCLUDES CORPORATE SEGEMENTED LOSS 10

11.
Business Segments
OVERVIEW & FINANCIAL
OUTLOOK – Targeted Therapies
• Revenue grew 9% over Q1/12; segment earnings
were down 54% due to higher spend in support of
sales and marketing, and Phase III clinical trials
• TheraSphere® revenue is expected to grow in the
mid-teen percentage range in fiscal 2013
• Phase III clinical trial spending is expected to be in
the range of $6-8 million in fiscal 2013
• Significant additional investments in fiscal 2013 to
support TheraSphere® long-term global growth
11

12.
Business Segments
OVERVIEW & FINANCIAL
OUTLOOK – Specialty Isotopes:
Sterilization Technologies
• Revenue increased by 2%
• Segment earnings were down 21% due to lower
Co-60 sales volumes
• In fiscal 2013, Sterilization Technologies
revenue is expected to be approximately the
same as in fiscal 2012; Co-60 revenue is
expected to be similar to fiscal 2012
• Fiscal 2013 quarterly profile of Co-60 revenue is
expected to be similar to fiscal 2012
12

13.
Business Segments
OVERVIEW & FINANCIAL
OUTLOOK – Specialty
Isotope: Medical Isotopes
• Revenues of $25.2 million and earnings of
$6.9 million in Q1 for Reactor, Cyclotron
isotopes and contract manufacturing
• Reactor isotopes revenue was $20.4
million, a decrease of 3% compared to
Q1/12
• Total Medical Isotopes revenue is expected
to decline in the mid-teen range in fiscal
2013, compared to the original annual
forecast of 20%
13

14.
First Quarter Fiscal 2013
Earnings Conference Call
March 6, 2013
www.nordion.com